Aug 13, 2018
Updated: Nov 20, 2020
Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing. Read more at Globe Newswire.